D) The cytotoxicity of unconjugated gemtuzumab antibody (2 μg/ml) against CD33+ patient-derived MDSCs from different cancer subtypes, compared to gemtuzumab ozogamicin (2 μg/ml) and untreated controls, as assessed by flow cytometry with propidium iodide staining. The gene discussed is CD33; the disease is cancer.